SCHEMBL4297480

SCHEMBL4297480

Nc1ccc(C(=O)Nc2nccs2)cc1C(F)(F)F

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 11/20 0.61
NPC1 O15118 11/20 0.61
SMN1; SMN2 Q16637 4/20 0.61
LMNA P02545 2/20 0.61
RECQL P46063 1/20 0.61
L3MBTL1 Q9Y468 1/20 0.61
MAPT P10636 2/20 0.57
POLB P06746 1/20 0.57
ESR2 Q92731 1/20 0.57
HSD17B10 Q99714 1/20 0.57
MEN1 O00255 2/20 0.56
KMT2A Q03164 2/20 0.56
MAPK1 P28482 1/20 0.54
GCK P35557 1/20 0.54
KDM4E B2RXH2 1/20 0.53
RXFP1 Q9HBX9 1/20 0.53
ALDH1A1 P00352 1/20 0.52
GAA P10253 1/20 0.52
SCD O00767 1/20 0.52
AGER Q15109 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2956673 0.84 RAB9A (0.71) RAB9ANPC1SMN1; SMN2LMNARECQL
SCHEMBL3199881 0.83 RAB9A (0.66) RAB9ANPC1SMN1; SMN2LMNARECQL
SCHEMBL4295163 0.82 RAB9A (0.60) RAB9ANPC1SMN1; SMN2LMNARECQL
SCHEMBL13122950 0.82 RAB9A (0.56) RAB9ANPC1SMN1; SMN2LMNARECQL
SCHEMBL3190864 0.81 RAB9A (0.66) RAB9ANPC1SMN1; SMN2LMNARECQL
SCHEMBL3200155 0.81 RAB9A (0.66) RAB9ANPC1SMN1; SMN2LMNARECQL
SCHEMBL3206087 0.81 RAB9A (0.66) RAB9ANPC1SMN1; SMN2LMNARECQL
SCHEMBL4289701 0.81 NPC1 (0.52) RAB9ANPC1SMN1; SMN2LMNARECQL
SCHEMBL4295386 0.78 ADORA2A (0.77) RAB9ANPC1SMN1; SMN2MAPTPOLB
SCHEMBL3188014 0.78 RAB9A (0.79) RAB9ANPC1SMN1; SMN2LMNARECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090247593-A1 N-THIAZOL-2-YL-BENZAMIDE DERIVATIVES H. LUNDBECK A/S (DK) 2009-10-01 US disclosed
EP-1803455-A1 N-thiazol-2-yl-benzamide derivatives H.Lundbeck A/S (DK) 2007-07-04 EP disclosed
EP-1682129-B1 N-THIAZOL-2-YL-BENZAMIDE DERIVATIVES LUNDBECK & CO AS H (DK) 2007-02-21 EP disclosed
CN-1870996-A N-thiazol-2-yl-benzamide derivatives LUNDBECK & CO AS H (DK) 2006-11-29 CN disclosed
US-20060154974-A1 N-thiazol-2-yl-benzamide derivatives H. LUNDBECK A/S (DK) 2006-07-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090247593-A1 N-THIAZOL-2-YL-BENZAMIDE DERIVATIVES ADORA2A, ADORA3, ADORA1 RAB9A 2380/4885NPC1 1022/4885SMN1; SMN2 1617/4885
US-20060154974-A1 N-thiazol-2-yl-benzamide derivatives ADORA2A, ADORA3, ADORA1 RAB9A 2380/4885NPC1 1022/4885SMN1; SMN2 1617/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.